Leonidas G Koniaris
Overview
Explore the profile of Leonidas G Koniaris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
215
Citations
5204
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Robinson T, Hamidi T, Counts B, Guttridge D, Ostrowski M, Zimmers T, et al.
Front Immunol
. 2023 Nov;
14:1207746.
PMID: 38022578
The development of cachexia in the setting of cancer or other chronic diseases is a significant detriment for patients. Cachexia is associated with a decreased ability to tolerate therapies, reduction...
2.
Robinson T, Milgrom D, Nagaraju S, Goggins W, Samy K, Koniaris L
Curr Oncol
. 2023 Aug;
30(8):7620-7626.
PMID: 37623033
Sarcomas are a rare tumor of mesenchymal origin. The liposarcoma is the most common sarcoma of the retroperitoneum. Liposarcomas are typically low grade, and present at an advanced stage and...
3.
4.
Sharygin D, Koniaris L, Wells C, Zimmers T, Hamidi T
Immunology
. 2023 Feb;
169(3):260-270.
PMID: 36840585
The cell surface antigen CD14 is primarily understood to act as a co-receptor for toll-like receptors (TLRs) to activate innate immunity responses to pathogens and tissue injury in macrophages and...
5.
Robinson T, Pebror T, Krosin M, Koniaris L
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831543
Surgical extirpation of liver tumors remains a proven approach in the management of metastatic tumors to the liver, particularly those of colorectal origin. Ablative, non-resective therapies are an increasingly attractive...
6.
Jengelley D, Wang M, Narasimhan A, Rupert J, Young A, Zhong X, et al.
Cytokine
. 2022 Sep;
159:155972.
PMID: 36054964
Musculoskeletal diseases such as muscular dystrophy, cachexia, osteoarthritis, and rheumatoid arthritis impair overall physical health and reduce survival. Patients suffer from pain, dysfunction, and dysmobility due to inflammation and fibrosis...
7.
Zhong X, Narasimhan A, Silverman L, Young A, Shahda S, Liu S, et al.
J Cachexia Sarcopenia Muscle
. 2022 May;
13(4):2146-2161.
PMID: 35510530
Background: Cachexia is frequent, deadly, and untreatable for patients with pancreatic ductal adenocarcinoma (PDAC). The reproductive hormone and cytokine Activin is a mediator of PDAC cachexia, and Activin receptor targeting...
8.
Narasimhan A, Zhong X, Au E, Ceppa E, Nakeeb A, House M, et al.
Cancers (Basel)
. 2021 Apr;
13(8).
PMID: 33923976
The vast majority of patients with pancreatic ductal adenocarcinoma (PDAC) suffer cachexia. Although cachexia results from concurrent loss of adipose and muscle tissue, most studies focus on muscle alone. Emerging...
9.
Rupert J, Narasimhan A, Jengelley D, Jiang Y, Liu J, Au E, et al.
J Exp Med
. 2021 Apr;
218(6).
PMID: 33851955
Most patients with pancreatic adenocarcinoma (PDAC) suffer cachexia; some do not. To model heterogeneity, we used patient-derived orthotopic xenografts. These phenocopied donor weight loss. Furthermore, muscle wasting correlated with mortality...
10.
Narasimhan A, Shahda S, Kays J, Perkins S, Cheng L, Schloss K, et al.
Cancers (Basel)
. 2020 Dec;
12(12).
PMID: 33334063
Patients with pancreatic ductal adenocarcinoma (PDAC) suffer debilitating and deadly weight loss, known as cachexia. Development of therapies requires biomarkers to diagnose, and monitor cachexia; however, no such markers are...